Not All Stem Cells Created Equal

Compared to induced pluripotent stem cells generated from somatic cells, stem cells created by nuclear transfer appear to be closer to the genetic state of embryonic cells.

Jul 2, 2014
Anna Azvolinsky

Human nuclear transfer embryonic stem cells expressing OCT-4 marker of early embryosCOURTESY OF OHSU CENTER FOR EMBRYONIC CELL AND GENE THERAPYIn the process of converting a somatic cell to a stem cell, researchers have questioned whether the resulting cells retain characteristics of their prior, non-stem-cell states. Applying two pioneering approaches to create human pluripotent stem cells from somatic cells—by inducing pluripotent stem cells (iPSCs) or using a process called somatic cell nuclear transfer (SCNT)—researchers from Oregon Health & Science University (OHSU) and their colleagues have compared the genomic and epigenomic landscapes of the resulting cell types. They found that the genomes of stem cells created through SCNT more closely match those of embryonic stem cells (ESCs) derived from early human embryos. The team’s comparative analysis was published today (July 2) in Nature.

Shoukhrat Mitalipov, a reproductive biologist and director of the Center for Embryonic Cell and Gene Therapy at OHSU, led the team that developed the SCNT approach just last year. For the present study, Mitalipov said he and his coauthors wanted to better understand the degree to which this new class of pluripotent cells were comparable to iPSCs.

Both iPSCs and SCNT-derived cells showed similar numbers of acquired genomic deletions and duplications. But while the iPSCs retained some of the epigenetic and gene expression patterns of their parental somatic counterparts, the SCNT-derived cells had transcriptional and epigenetic patterns that were more like in vitro fertilized (IVF) ESCs, which are considered the most authentic form of ESCs, as they are directly isolated from human embryos.

Unlike IVF ESCs, however, patient-derived somatic cells reprogrammed into pluripotent stem cells present a better opportunity for patient-tailored therapies—they overcome the issue of donor-recipient matching. Both SCNT-derived cells and IPSCs mimic the characteristics of true ESCs, but previous studies have shown that iPSCs can acquire both epigenetic and transcriptional aberrations during the stem-cell conversion process. The present study is the first to compare the genetic variability of SCNT-derived cells to that of IVF ESCs, showing that the somatic-to-stem-cell conversion results in the acquisition of these aberrations and is not somehow secondary to this process.

“This is an extremely important study showing that differences exist between stem cells made by nuclear transfer compared to reprogramming by transcription factors [to create iPSCs],” George Daley, a stem cell biologist at Children’s Hospital Boston and Harvard Medical School, told The Scientist in an e-mail. “It suggests that reprogramming by nuclear transfer may be slightly more effective than reprogramming by transcription factors.”

Mitalipov and his colleagues started with fetal human dermal fibroblasts (HDFs) from the same source, creating four SCNT-derived pluripotent stem cell lines and seven iPSC lines. The iPSC method involves turning on four key early embryonic transcription factors, while the SCNT approach requires the transfer of the nucleus from the skin cell into a nucleus-lacking donor egg cell. The two IVF ESC lines analyzed in the current study came from the same egg donor used to create the SCNT-based cell lines. 

The genomic methylation patterns of the SCNT-derived cells more closely matched those of IVF ESCs compared to those of the iPSCs, the researchers found. There were 6,478 differentially methylated sites between the iPSCs and the IVF ESCs, compared to only 110 such sites that differed between the IVF ESCs and SCNT-derived cells.

While both reprogrammed stem cell types preserved some of their parental epigenetic memory, the iPSCs retained eight-fold more of these methylation sites. “For both [stem cell types], there are genomic regions that look like the original fibroblast line but there are far fewer in the stem cells made by nuclear transfer,” said study coauthor Joseph Ecker, who directs the Salk Institute’s Genomic Analysis Laboratory. “There is still room for improving both methods,” Ecker added. “We need to understand what characteristics and processes are still lacking [in these pluripotent cells] to bring them to the ideal epigenetic reprogrammed state.”

“This is an extensive analysis and a first look at comparing the cells made with these two different methods,” said Dieter Egli, a regenerative medicine specialist at the New York Stem Cell Foundation and Columbia University.

But the functional significance of the differences observed between these types of stem cells must still be addressed, he added. Because the stem cell lines analyzed all came from a single somatic cell source, it will be important to extend these analyses to other stem cell lines, before drawing conclusions, said Egli.

Daley agreed. “What remains unknown is whether these differences, which are overall quite minor, will compromise the value of iPS cells in any way,” he told The Scientist. There are already clinical trials planned to evaluate patient-derived iPSCs. An important question is whether SCNT-derived cells provide an advantage over iPSCs for use in disease modeling and cell-based therapies to justify the increased effort in generating them, said Daley.

Also unknown is whether the age of the somatic cell from which stems cell are derived matters for therapeutic use. For the present study, Mitalipov’s team used fetal fibroblasts. But other studies, including one from the Egli laboratory, have shown that the technique works even with cells taken from adult patients. Whether the age of the donated nucleus affects reversion back to a stem-cell state is something that Ecker and Mitalipov would now like to investigate. The researchers also plan to analyze other epigenetic signatures of these different stem cell lines, including histone modifications.

H. Ma et al., “Abnormalities in human pluripotent cells due to reprogramming mechanisms,” Nature, doi:10.1038/nature13551, 2014.

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets


Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.